Person: KOCAKAYA, DERYA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KOCAKAYA
First Name
DERYA
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication Metadata only Does preexisting immuncompromised status prevent mortality in COVID-19 patients: friend or foe?(2022-09-01) VEZİR, DUYGU; KOCAKAYA, DERYA; MERCANCI, ZEYNEP; KARAKURT, SAİT; Vezir D., Yildizeli S. O., KOCAKAYA D., Mercanci Z., Balcan B., Cinar C., Eryuksel E., KARAKURT S.Publication Open Access Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients— case series(2022-01-01) AKSOY, AYSUN; BOZKURTLAR, EMİNE; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; İNANÇ, GÜZİDE NEVSUN; KOCAKAYA, DERYA; AKSOY A., KOCAKAYA D., Yalçinkaya Y., BOZKURTLAR E., KARAKURT S., Eryüksel E., İnanç N.© TÜBİTAK.Background/aim: Rheumatoid pulmonary nodule can be detected in up to 32% of rheumatoid arthritis (RA) patients and approximately one-third of nodules may cavitate. We aimed to evaluate characteristics of patients with RA developing cavitary pulmonary nodular (CPN) lesions under disease-modifying antirheumatic drugs (DMARDs), follow-up of both cavitary and solid nodules, and their outcome with the treatment. Materials and methods: RA patients who presented with CPN lesions during follow-up were recruited retrospectively in this case series analysis. Total numbers and mean diameters of cavitary and solid nodules in each thorax computed tomography (CT) have been determined and followed up by two experienced pulmonary physicians. Moreover, changes in treatment after the development of the CPN lesions and characteristics of cavitary nodules were collected. Results: Eleven patients with CPN lesions were reported. At the time of CPN diagnosis, more patients were taking leflunomide than methotrexate (81% vs 19%). Half of the patients were receiving biologic therapy and only 18% were taking anti-TNF drugs. After a median of 24 (3–65) months of follow-up, the regression of CPN lesions was determined in 45% (5/11) of patients. Four of these 5 (80%) patients were switched to a treatment regimen without leflunomide and three of them to nonanti-TNF biologic treatment or targeted synthetic DMARDs (tocilizumab, tofacitinib, and rituximab). Conclusion: CPN lesions seen in RA patients are often pulmonary manifestations of the underlying disease; however, one must rule out malignancies or infections. If lesions progress under DMARDs, it is advised to discontinue synthetic DMARDs (LEF/MTX) and switch to another biological DMARD with different modes of action.Publication Metadata only Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic(2024-01-01) ÜNDER, DUYGU; ENVER, CÜNEYD; DEMİRCİ, MUHAMMED YASİR; AYHAN, YUNUS EMRE; ÖZGAN, BETÜL; İLERLER, ENES EMİR; OKUYAN, BETÜL; ERTÜRK ŞENGEL, BUKET; KOCAKAYA, DERYA; SİLİ, ULUHAN; TİGEN, ELİF; KARAKURT, SAİT; KORTEN, VOLKAN; SANCAR, MESUT; ÜNDER D., ENVER C., DEMİRCİ M. Y., AYHAN Y. E., ÖZGAN B., İLERLER E. E., OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al.Objectives: Drug-related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist-led medication review in hospitalized probable patients with coronavirus disease-2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in Türkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician’s acceptance rate of clinical pharmacists’ recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug-related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.Publication Open Access Malign melanom, endobronşial metastaz(2009-04-09) KOCAKAYA, DERYA; OLGUN YILDIZELİ, ŞEHNAZ; ERYÜKSEL, SEMİHA EMEL; ÇELİKEL, ÇİĞDEM; KARAKURT, SAİT; Kocakaya D., Abul Y., Olgun Yıldızeli Ş., Eryüksel S. E., Tosuner Z., Yazıcı Z., Çelikel Ç., Karakurt S.Amaç: Malign melanoma melanositlerin malign transfomayonu sonucu gelişir.Pulmoner metastazını pulmoner arterlere ulaşan tümör embolileri yoluyla yapar.Endobronşial yayılımlı malign melonom vakaları sınırlı sayıdadır. Gereç ve Yöntem: Nadir görülen endobronşial yayılım yapmış bronkoskopi ile tanı koyduğumuz vakamızı sunduk. Bulgular: 42 yaşında bayan hasta nefes darlığı şikaye ile başvurdu. 2006 da tanı konan sır a konjenital dev nevüs tanısı mevcu u.5 paket/yıl sigara hikayesi mevcu u. Fizik muayenede bel bölgesinde 25x15 cm boyularında yaklaşık tüm lumbar bölgeyi kaplayan gluteal bölgeye de yayılan dev nevüsü mevcu u. Vücu a özellikle sır a ve saçlı deride birden fazla çok sayıda nevüsler izlendi. Nevüslerde renk değişikliği tariflemiyordu. Sır aki dev nevüste kalınlaşma belir yordu. Solunum sistemi muayenesi doğaldı.Aksiller ele gelen 1x2 cm lik lenfadenopa si mevcu u. PA akciğer grafisinde sol hilar bölgede düzensizlik ve dansite ar şı mevcu u. Toraks BT’de sol üst lobda 40x30 mm kitlesel lezyon mevcu u. Bronkoskopide sol akciğer üst lob girişinde nevüs tarzında siyahımsı mukozadan kabarık endobronşial lezyon izlendi. Alınan bronkoskopik biyopsi, rça ve bronkoalveolar lavaj materyalleri malign melonom ile uyumlu geldi. Sonuç: Malign melanoma bağlı endobronşial metastaz nadirdir. Literatürde 1966-2002 yılları arası yapılmış geniş taramada 204 akciğer dışı kaynaklı endobronşial metastaz vakası saptanmış olup bunları sırasıyla meme(%35), böbrek(%17), kolon ve rektum(%15) oluşturmaktadır.. Deri kanseri vakaları sadece 9 vaka olup , 7’si malign melanom kökenli saptanmış r. Tanıda primer akciğer kanserinden ayırtetmek için bronkoskopi şar r. Malign melannomaya bağlı endobronşial metastazı olgumuzu literatürde nadir görülmEsi nedeniyle sunduk.Publication Metadata only Increased D-dimer is associated with disease progression and increased mortality in Turkish COVID-19 patients(2023-05-31) MERCANCI, ZEYNEP; ILGIN, CAN; OLGUN YILDIZELİ, ŞEHNAZ; KOCAKAYA, DERYA; BALCAN, MEHMET BARAN; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; Mercanci Z., ILGIN C., Yildizeli S. O., KOCAKAYA D., Balcan B., Sengel B. E., KARAKURT S., Eryuksel E.Objective: Coagulopathy is thought to play an important role in the development of severe COVID-19. High D-dimer levels have been reported in Chinese cohort studies. However, ethnicity has significant implications for thrombotic risk. Our aim in this study is to determine the effect of D-dimer measurements on disease prognosis and mortality in Turkish patients with COVID-19. Patients and Methods: The study was designed retrospectively. Patients over the age of 18 who were admitted to our hospital were included in the study. Results: The study included 226 patients. According to the World Health Organization staging, 75(33.2%) patients, according to the staging of Siddiqi et al., 67 (29.7%) patients progressed. In the ROC analysis performed to predict mortality, AUC value for D-dimer was found to be 82.25% (95%CI 74.8%-89.71%). When the cut-off value for D-dimer was accepted as ≥3.25mg/L, specificity was 94.15%, correctly classified rate 88.5%, positive likelihood ratio as (LR):5.69, negative LR:0.71. Conclusion: As a result, similar to the Chinese cohorts, elevated D-dimer measurements increase disease progression and mortality in Turkish patients with COVID-19. D-dimer levels of 3.25 mg/L and above, strongly determine the risk of increased mortality in the Turkish Caucasian ethnic group.